Zepbound, from drugmaker Eli Lilly, is already approved for people who are obese or overweight and have a related health condition, such as type 2 diabetes, high cholesterol or high blood ...
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone ...
Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just ...
Berkshire Hathaway was briefly a member of the group, but its market cap has dipped slightly below the threshold this month.
"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback